Evergreen Theragnostics

Evergreen Theragnostics, founded in 2018 and based in Springfield, United States, was a private company operating in the oncology and diagnostics sectors with a focus on radiopharmaceuticals. Its business model combined services (manufacturing for partners) with therapeutics/diagnostics development, positioning it in the growing theragnostic market. The company has been acquired by Lantheus, indicating its technology and capabilities were of strategic value to a larger player in the field.

Radiopharmaceutical theragnostic development, manufacturing, and commercialization platform.

The radiopharmaceutical theragnostic market is highly competitive, dominated by Novartis (with Pluvicto and Lutathera) and including other large players like Bayer and emerging biotechs. Evergreen, now part of Lantheus, competes as an integrated developer and manufacturer, but must contend with both large pharma's R&D scale and the innovation of smaller, agile biotech companies.